After obtaining manufacturing and marketing approval from the Drugs Controller General of India (DCGI), the drug company Glenmark Pharmaceuticals released Favipiravir, under the brand name Fabiflu, to treat patients with light to moderate COVID-19.
Fabiflu Tablet for Corona virus:
At a price of ₹103 per tablet, the prescribed medication will be available in the form of a 200 mg tablet in an MRP of 3500 rupees for a strip of 34 Fabiflu tablets.
He added that Fabiflu medicine for COVID 19 is the first oral medication approved by favipiravir in India.
The pharmaceutical company said it is a prescribed drug with a recommended dose of 1800 mg twice on the first day, then 800 mg twice a day until the 14th day.
When asked about the company’s ability to manufacture the drug, the pharmaceutical company said:
Trails on Patients:
“Given a minimum of two tapes per patient, Glenmark will be able to provide FabiFlu to approximately 82,500 patients in the first month itself. We will closely follow the development and basis of the situation, and we will expand the country’s health care needs and meet their needs”.
The company manufactures active pharmaceutical ingredients (APIs) for its products at the Ankleshwar plant and the formulations are manufactured at the Baddi plant.
Glenmark said the drug will be available both in hospitals and on the retail channel.
When asked if the company was seeking links with hospitals to supply the drug, he said,
“Our effort now is to prioritize manufacturing to ensure that FabiFlu available in India to all patients who need it.” Glenmark will definitely consider supporting public and private healthcare facilities and will organize other appropriate options as needed and on time. ”
The Mumbai-based company on Friday obtained manufacturing and marketing approval from the Drugs Controller General of India (DCGI).
This approval comes when the number of trials in India has never been faster and puts a lot of pressure on our healthcare system. The company is using effective treatments like Fabiflu.
He hopes it will relieve the pressure and provide Indian patients with the necessary and timely information and Glenmark (Chairman and MD Glenn Saldanha)said treatment options, “Glenmark will work closely with governments and the medical community.
They added that it is an oral product, which is a great advantage, especially when the hospital infrastructure is under tension.
He added that the limited use of approval implies responsible use of medication and that all patients must sign informed consent before starting treatment.
Favipiravir can be used in patients with coronaviruses who have comorbid conditions such as diabetes and heart disease with mild to moderate COVID-19 symptoms, said Glenmark.
How to use Fabiflu:
It was a prescription drug with a recommended dose of 1800 mg twice daily on day 1, followed by 800 mg twice daily until day 14.
The tablets are produced by the company at its Baddi plant in Himachal Pradesh. The drug will be available in hospitals and retail outlets, said Glenmark.
Glenmark also announced last month that he was conducting another clinical study to evaluate the effectiveness of two antiviral drugs, umifenovir, and favipiravir, as a combination therapy in patients with a moderately hospitalized coronavirus in India.
Fabiflue Glenmark is the first oral medication of favipiravir-approved by India for the treatment of COVID-19 patients in India.